Analysis of peripheral blood lymphocyte phenotype and function during dexamethazone treatment of progressive multiple sclerosis. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Analysis of peripheral blood lymphocyte phenotype and function during dexamethazone treatment of progressive multiple sclerosis.

Acta Neurol Scand. 1991 Aug;84(2):91-7. Unique Identifier : AIDSLINE MED/92057586
Salmaggi A; Baldetorp B; Milanese C; Nespolo A; Parma R; Sandberg-Wollheim M; Department of Neurology, University Hospital, Lund, Sweden.

Abstract: Five patients with chronic progressive multiple sclerosis (MS) and three control patients with lumbar disc herniation were treated with dexamethazone during 14 days. The effect on peripheral blood T-cell subsets and on the proliferative response of peripheral blood mononuclear cells (PBMC) to pokeweed mitogen (PWM) and anti-mu antibody was analyzed. Before treatment, the proportion of CD3+ and CD4+ PBMC was similar in MS and control patients, but the proportion of CD8+ and DR+ PBMC was lower and the PBMC were less responsive to anti-mu stimulation in MS patients compared to controls. Steroid treatment induced reversible granulocytosis and lymphocytosis. CD3+ and CD4+ cells increased and DR+ cells decreased in MS patients but not in controls. Proliferation of anti-mu stimulated PBMC increased in MS-patients during the two weeks of treatment, but decreased in controls. The enhancement in the MS patients of pre-existing immune abnormalities suggests that a cautious attitude is warranted in the use of steroid treatment in chronic progressive MS.
Keywords: Adult Antigens, Differentiation, T-Lymphocyte/ANALYSIS CD4-CD8 Ratio/DRUG EFFECTS Dexamethasone/*THERAPEUTIC USE Female Human HLA-DR Antigens/ANALYSIS *Immunophenotyping Leukocyte Count/DRUG EFFECTS Lymphocyte Transformation/*DRUG EFFECTS/IMMUNOLOGY Male Middle Age Multiple Sclerosis/*DRUG THERAPY/IMMUNOLOGY Neurologic Examination Receptors, Antigen, T-Cell/ANALYSIS Support, Non-U.S. Gov't JOURNAL ARTICLEKWDadultantigens,differentiation,t-lymphocyte/analysiscd4-cd8ratio/drugeffectsdexamethasone/KWDtherapeuticusefemalehumanhla-drantigens/analysisKWDimmunophenotypingleukocytecount/drugeffectslymphocytetransformation/KWDdrugeffects/immunologymalemiddleagemultiplesclerosis/KWDdrugtherapy/immunologyneurologicexaminationreceptors,antigen,t-cell/analysissupport,non-uKWDsKWDgov'tjournalarticle
920228
M9220201

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .